Anjali Patel
Associate Editor
Loyola University Chicago School of Law, JD 2028
The White House has secured pricing agreements from 26 drugmakers in exchange for relief from new tariffs on imported drugs. Since September 2025, Pfizer and other large drug manufacturers have signed these agreements, referred to as most-favored-nation agreements (MFN Agreements). Under them, drug manufacturers commit to lowering U.S. drug prices to match the lowest prices paid in other developed nations, and in return they receive relief from the new tariffs. As of August 2026, 26 companies, encompassing 89% of the branded drug market, have entered into an MFN Agreement. However, many smaller drug manufacturers are left in the dark about how to qualify for that relief, and because the agreements are negotiated privately and the relief ends in January 2029, those companies face real compliance risk. To address this, HHS should publish standard MFN Agreement terms, HHS and the Commerce Department should set clear rules and deadlines for exemptions, and Congress should decide whether these commitments last beyond this administration.
Sign a deal, skip the tariff
In April 2026, President Trump invoked the power granted to him under the Trade Expansion Act of 1962, directing the federal government to restrict imports that threaten national security. Under that direction, the federal government has now imposed a 100% tariff on certain imported patented drugs and their associated ingredients. Generic drugs and similar low-cost versions of brand-name medicines are currently excluded.
Companies can lower that tariff by signing an MFN Agreement with the Department of Health and Human Services (HHS). A drug manufacturer that signs an MFN Agreement and promises to manufacture more of its drugs in the U.S. is not required to pay a tariff until January 20, 2029. Companies that merely promise to make drugs in the U.S. still have to pay a 20% tariff on their imported patented drugs, which will rise to a 100% tariff in April 2030. The tariffs first took effect on July 31, 2026, for the 17 large drug manufacturers named in the April proclamation. On September 29, 2026, they reached the rest of the branded drug market. Now, smaller companies have to choose between making a deal and paying a tariff.
Big pharma’s head start
Large drug companies have had about a year to negotiate with HHS over lower U.S. drug prices, and with the Department of Commerce over U.S. manufacturing plans, in exchange for tariff relief, with some securing agreements months before the tariffs took effect. The White House approached the largest manufacturers first, so mid-sized drug developers, left off the first tariff list, are only now under pressure to accept deals that may not fit their smaller budgets and limited manufacturing capacity. The Midsized Biotech Alliance of America, a new trade group, calls this an unfair two-tiered system: companies that signed MFN Agreements are fully exempt, while mid-sized companies that depend on a few patented medicines absorb the cost. Its objection matters because small and mid-sized biotech companies develop more than half of all approved medicines, according to the Biotechnology Innovation Organization.
Those exemptions come with strings attached. The MFN Agreements, signed with HHS, also give state Medicaid programs the same low prices. In return, BioCentury, a biotech industry news outlet, reported that drugmakers get tariff relief and an exemption from mandatory Medicare pricing rules which could otherwise force price cuts on drugs sold to older Americans. Mid-sized companies are now signing similar terms. One has announced Medicaid prices matching those in other developed countries and the same prices for newly launched drugs across all U.S. payers. Yet public details about which drugs are covered and what discounts apply remain limited.
From private deals to public rules
HHS’s approach of negotiating MFN Agreements one company at a time has produced results. According to the White House, nine mid-sized drugmakers alone committed at least $19.6 billion to U.S. manufacturing, and state Medicaid programs gained access to lower prices. But private terms and a short deadline create problems for the drugmakers. The tariff exemption tied to an MFN Agreement ends January 20, 2029, leaving it unclear what tariff rate companies that cut prices and built factories will face afterward. Industry watchers also warn the pressure could push smaller companies to sell to larger ones or scale back, undermining the goal of strengthening U.S. drug development.
Three steps would help. HHS could publish standard MFN Agreement terms so companies know what they are signing and Congress can see what it would be extending. HHS and the Commerce Department could set clear exemption criteria and deadlines. Congress could then require disclosure of the terms or write the commitments into law, so they outlast this administration.
The MFN Agreements may bring lower prices and new factories, but they are negotiated privately, with an exemption that ends in January 2029. That leaves smaller drug companies unable to tell what an MFN Agreement requires, how to get Commerce approval of a manufacturing plan, or what happens when the exemption ends. Until HHS, Commerce, and Congress make the terms public and the exemption process clear, smaller drug developers will keep making costly decisions without knowing the rules, and the government will keep risking the domestic drug development it says it wants to protect.